التاريخ:	--/--/-- --:--:--
مُعرِّف الحدث:	E5DRE4AUD
نوع الإجراء:	ACQUISITION
حالة الإجراء:	ANNOUNCED
رمز سهم الشركة المستحوِذة:
الرمز المُستهدَف:	CDTX
مُحدَّث:	--/--/-- --:--:--
سعر شراء السهم:	221.5
عملة سعر السهم الواحد:	USD
مصادر الأخبار:	https://www.businesswire.com/news/home/20251114185276/en/

ملاحظات حول الإجراء

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (Nasdaq: CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion. The transaction has been approved by both Merck's and Cidara's Boards of Directors. Under the terms of the merger agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Cidara. The acquisition is subject to a majority of Cidara's stockholders tendering their shares in a tender offer that will be initiated by a subsidiary of Merck. The closing of the proposed transaction will be subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the first quarter of 2026 and is expected to be accounted for as an asset acquisition.